|
GB0220319D0
|
|
Enzyme activated self-immolative nitrogen mustard drugs
|
|
GB0214789D0
|
|
Substrate for holding an array of experimental samples
|
|
AU4889102A
|
|
Papillomavirus vaccine
|
|
GB0212720D0
|
|
Substrate for holding an array of experimental samples
|
|
GB0119863D0
|
|
DNA-PK inhibitors
|
|
GB0119865D0
|
|
DNA-PK inhibitors
|
|
GB0101686D0
|
|
Cyclin dependent kinase inhibitors
|
|
US6677345B1
|
|
Cyclin dependent kinase inhibitors
|
|
GB0016162D0
|
|
Indole-3-acetic acid derivatives
|
|
GB0011060D0
|
|
Improvements relating to gene directed enzyme prodrug therapy
|
|
GB0010191D0
|
|
Assays, methods and means
|
|
GB0007401D0
|
|
Substituted chalcones as therapeeutic compounds
|
|
GB0001051D0
|
|
Materials and methods relating to the identification and sequencing of the cyldsusceptibility gene and uses therof
|
|
GB0000940D0
|
|
Nucleic acid analysis method
|
|
GB9927444D0
|
|
Inhibiting gene expression
|
|
AU5013099A
|
|
Papillomavirus vaccine
|
|
GB9919673D0
|
|
2-Arlybenzazole compounds
|
|
GB9916810D0
|
|
Killing cells
|
|
GB9915853D0
|
|
Assay method and users thereof
|
|
GB9913359D0
|
|
Polymer modified biological elements
|
